Abstract CD19‐directed chimeric antigen receptor (CAR) T‐cell therapy has had a dramatic impact on the natural history and survival of patients with high‐risk B‐cell non‐Hodgkin lymphoma. Accompanying this success has been the development of new fields of medicine and investigation into toxicity risks and mitigation therapies, mechanisms of resistance and the development of novel and next generation products and strategies in order to address relapse, and issues related to global access and health care economics. This article is a survey of each of these areas as it pertains to the rapidly evolving field of CAR T‐cell therapy, written by an International community of lymphoma experts, who also happen to be women.